Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27553229 | 0.85 | AOC3 (0.56) | L3MBTL1AOC3ALDH1A1MAPTFFAR1 | |
| SCHEMBL27553231 | 0.85 | AOC3 (0.56) | L3MBTL1AOC3ALDH1A1MAPTFFAR1 | |
| SCHEMBL11071292 | 0.84 | L3MBTL1 (0.61) | L3MBTL1AOC3TNFCA1CA2 | |
| SCHEMBL4478666 | 0.84 | FFAR1 (0.56) | L3MBTL1AOC3ALDH1A1MAPTFFAR1 | |
| SCHEMBL4478662 | 0.84 | FFAR1 (0.56) | L3MBTL1AOC3ALDH1A1MAPTFFAR1 | |
| SCHEMBL27702953 | 0.84 | TNF (0.55) | L3MBTL1TNFCA1CA2PARP10 | |
| SCHEMBL29161398 | 0.83 | AOC3 (0.54) | L3MBTL1AOC3TNFCA1CA2 | |
| SCHEMBL12883281 | 0.82 | TNF (0.54) | L3MBTL1AOC3TNFCA1CA2 | |
| SCHEMBL5468798 | 0.82 | AOC3 (0.57) | L3MBTL1AOC3CA1CA2ALDH1A1 | |
| SCHEMBL6289377 | 0.81 | TNF (0.52) | L3MBTL1AOC3TNFCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | claimed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | claimed |
| JP-2007522197-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | claimed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | claimed |
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2021-03-11 | — | — | US | disclosed |
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | disclosed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | EBP, NR1H3, APEH | L3MBTL1 4155/4885AOC3 371/4885TNF 2425/4885 |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | L3MBTL1 4725/4885AOC3 378/4885TNF 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.